SCHEMBL13699252

SCHEMBL13699252

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)c3ccc(OC4CC5CCC(C4)N5CC)cc3)cc2)c(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.44
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
MCHR1 Q99705 7/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
FGFR1 P11362 1/20 0.40
NAMPT P43490 2/20 0.40
MAPT P10636 3/20 0.38
GAA P10253 2/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4229209 0.94 PKM (0.43) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL13699277 0.94 PKM (0.45) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL13699253 0.93 MCHR1 (0.43) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL13699320 0.93 PKM (0.42) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL13699167 0.93 MAPT (0.42) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL13699258 0.92 PKM (0.44) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL13699257 0.92 PKM (0.41) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL13699169 0.92 MCHR1 (0.42) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL13699175 0.91 PKM (0.40) PKMRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL13699349 0.90 MCHR1 (0.42) PKMRAB9ASMN1; SMN2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885RAB9A 2492/4885SMN1; SMN2 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.